Key Points CRISPR Therapeutics will likely be a much larger company in 10 years. Much of that time will be spent refining the technologies it already has in hand today. It'll probably hit a few bumps along the road even if its most ambitious bets pay off. 10 stocks we like better than CRISPR Therapeutics › Technically sophisticated gene-editing biotechs like CRISPR Therapeutics (NASDAQ: CRSP) could become dramatically more capable over the next 10 years if their most ambitious plans come to fruition. If that happens, it'd likely make those who invest today much wealthier. But where exactly will CRISPR Therapeutics be in 2036, given what it's doing today and what it wants to do tomorrow? Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.